Financial Performance - The audited net profit attributable to shareholders for 2024 is CNY 274,027,809.74, with the parent company's distributable profit at CNY 795,682,511.91[7]. - The proposed cash dividend for 2024 is CNY 3.40 per 10 shares (including tax), with no bonus shares or capital reserve conversion[7]. - The company achieved a revenue of approximately CNY 2.14 billion in 2024, representing a year-on-year increase of 31.16%[25]. - The net profit attributable to shareholders decreased by 6.38% to approximately CNY 274 million in 2024[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 9.08% to approximately CNY 268 million[25]. - The net cash flow from operating activities decreased by 61.30% to approximately CNY 107 million, primarily due to increased tax payments and employee compensation[26]. - The company's total assets increased by 9.30% to approximately CNY 3.19 billion at the end of 2024[25]. - The company’s equity attributable to shareholders increased by 3.88% to approximately CNY 1.53 billion at the end of 2024[25]. - The company reported an operating revenue of CNY 2,144.39 million for the year 2024, marking a year-on-year growth of 31.16%[74]. Risk Management - The report includes a risk statement regarding forward-looking statements, indicating potential challenges and risks that may affect future development[8]. - The company emphasizes the importance of considering industry development trends and operational conditions when making profit distribution decisions[7]. - The company’s management discussion highlights potential risks and challenges in future operations, which do not constitute a commitment to investors[10]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures for external guarantees reported[9]. Operational Developments - The company established a nationwide OTC direct sales network, adding 13 provincial branches and a professional marketing team of over 1,700 members[36]. - The revenue from the OTC channel significantly increased, surpassing that of the prescription channel, enhancing the company's resilience to policy risks[36]. - The company plans to invest in the biopharmaceutical sector as part of its strategic layout for future growth[36]. - In 2024, the company expanded its OTC channel coverage by adding 27 major chain pharmacies and over 800 small chain pharmacies, achieving a multi-layered terminal system with over 60,000 third-party terminals[37]. - The company established deep partnerships with major e-commerce platforms like JD Health and Alibaba Health, resulting in significant growth in online sales revenue through data-driven product selection and marketing[38]. Research and Development - The company initiated 11 new R&D projects for core products, with 3 projects making significant progress, and published 11 academic papers to support prescription channel sales[39]. - The smart factory completed its construction by April 2024, enhancing production quality and efficiency through standardized, automated, and intelligent processes[40]. - The company implemented a data-driven management system, improving decision-making speed and accuracy through real-time operational data updates and integrated data governance[42]. - The company’s R&D investment amounted to RMB 2,313.92 million, representing 1.06% of operating revenue, with a year-on-year increase of 2.28%[110]. - The company’s investment in core product re-evaluation research totaled RMB 937.33 million, contributing to ongoing product development efforts[110]. Market Trends and Industry Insights - The pharmaceutical manufacturing industry in China saw a 3.4% year-on-year increase in value added, reversing a previous decline of 5.2%[48]. - The population aged 65 and above reached 220 million in 2024, driving demand for chronic disease treatment and health management, thus stabilizing drug consumption[49]. - The pharmaceutical manufacturing industry is experiencing resilient growth driven by innovation, digital transformation, and internationalization strategies despite challenges such as shrinking profit margins[50]. - The overall policy direction emphasizes "innovation-driven, structural optimization, and compliance upgrading" to facilitate high-quality industry development[59]. - The focus on digital transformation in traditional Chinese medicine aims to integrate big data and AI technologies over the next 3-5 years, enhancing the industry's modernization[55]. Governance and Compliance - The company’s governance structure includes a clear division of responsibilities among the shareholders' meeting, board of directors, and supervisory board, ensuring compliance with legal regulations[138]. - The company has held three shareholders' meetings in 2024, all of which complied with legal and procedural requirements[140]. - The company has established a comprehensive internal control system, enhancing management effectiveness and risk control[175]. - The internal control audit report for 2024 received a standard unqualified opinion from the auditing firm[177]. - The company has not faced any penalties from securities regulatory authorities in the past three years[151]. Environmental Responsibility - The company has invested 1,480,500 RMB in environmental protection during the reporting period[179]. - Guizhou Sanli Pharmaceutical Co., Ltd. has established a wastewater treatment plant with a capacity of 400 tons per day, achieving COD and ammonia nitrogen removal rates exceeding 98%[183]. - Guizhou Hanfang Pharmaceutical Co., Ltd. has a wastewater treatment plant with a capacity of 800 tons per day, achieving COD and ammonia nitrogen removal rates above 98%[185]. - The company remains compliant with pollution discharge standards, with all monitored pollutants meeting regulatory requirements[181]. - The company has implemented a comprehensive environmental monitoring strategy to ensure compliance with regulatory standards[196]. Employee Engagement and Compensation - The total number of employees in the parent company is 2,091, with a total of 2,852 employees across the parent and major subsidiaries[159]. - The company has established a performance-based compensation system linked to job value and contribution, aiming to enhance employee motivation[160]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 694.11 million yuan[148]. - The company has conducted 283 training sessions during the reporting period to enhance employee skills and strengthen corporate culture[161]. - The company has adjusted its cash dividend policy for the years 2024-2026, which was approved in a recent shareholders' meeting[162].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 408,589,489.70, a decrease of 3.18% compared to CNY 422,024,144.62 in the same period last year[4] - Net profit attributable to shareholders was CNY 41,946,770.84, down 25.16% from CNY 56,048,131.61 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 38,582,237.18, reflecting a decline of 31.56% compared to CNY 56,375,781.05 in the previous year[4] - Operating profit for Q1 2025 was CNY 47,244,699.17, down 31.6% from CNY 69,106,865.79 in Q1 2024[17] - The net profit for Q1 2025 was CNY 42,536,659.52, a decrease of 25.2% compared to CNY 56,860,529.64 in Q1 2024[18] - The company’s total comprehensive income for Q1 2025 was CNY 42,536,659.52, down from CNY 56,860,529.64 in Q1 2024, a decrease of 25.2%[18] Cash Flow - The net cash flow from operating activities was negative CNY 15,082,051.92, a significant decrease of 346.95% from CNY 6,107,280.58 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was negative at CNY -15,082,051.92, compared to a positive CNY 6,107,280.58 in Q1 2024[22] - Total cash inflow from operating activities in Q1 2025 was CNY 455,154,437.28, slightly down from CNY 464,880,944.73 in Q1 2024[22] - Cash outflow from operating activities increased to CNY 470,236,489.20 in Q1 2025, compared to CNY 458,773,664.15 in Q1 2024, marking an increase of 2.5%[22] - The net cash flow from investing activities was CNY -209,654,656.82 in Q1 2025, significantly worse than CNY -10,385,541.40 in Q1 2024[23] - Cash inflow from financing activities in Q1 2025 was CNY 119,156,787.76, compared to CNY 24,200,000.00 in Q1 2024, indicating a substantial increase[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,144,369,139.65, a decrease of 1.50% from CNY 3,192,107,890.63 at the end of the previous year[5] - Total liabilities amounted to CNY 1,503,503,195.92, a decrease from CNY 1,597,480,848.71[14] - Total equity attributable to shareholders was CNY 1,572,831,702.50, an increase from CNY 1,527,340,401.45[14] - Cash and cash equivalents decreased to CNY 55,335,081.52 from CNY 22,945,081.52[12] - Accounts receivable increased to CNY 769,390,951.04 from CNY 728,669,788.22[12] - Inventory increased to CNY 347,636,773.07 from CNY 320,722,064.52[12] Shareholder Information - Basic and diluted earnings per share were both CNY 0.10, down 28.57% from CNY 0.14 in the previous year[4] - The company reported an increase in the number of ordinary shareholders to 26,433 by the end of the reporting period[8] - Basic and diluted earnings per share for Q1 2025 were both CNY 0.10, down from CNY 0.14 in Q1 2024, representing a decline of 28.6%[18] Costs and Expenses - Total operating costs for Q1 2025 were CNY 360,500,086.77, an increase of 1.0% from CNY 354,161,051.46 in Q1 2024[17] - Research and development expenses for Q1 2025 were CNY 7,416,057.12, a decrease of 16.5% compared to CNY 8,891,832.83 in Q1 2024[17] - The decline in net profit attributable to shareholders was mainly due to rising material costs[6] Non-Recurring Items - Non-recurring gains and losses totaled CNY 3,364,533.66, primarily due to government subsidies and other income[6]

贵州三力制药股份有限公司 2025 年度财务预算报告 贵州三力制药股份有限公司（以下简称"公司"）2025 年度财务预算报告 编制工作已经完成。本预算报告遵循谨慎性原则，在公司中长期发展战略框架内， 综合 2025 年宏观经济预期与企业产品需求预期，目前生产排产计划、新业务拓 展计划等因素，在公司预算基础上，按合并报表的要求进行编制。 现受董事会委托，向本次会议作 2025 年度财务预算报告，请予以审议。 一、预算工作安排情况 2025 年公司财务预算是根据公司以前年度的实际经营情况、财务状况和经 营成果，结合公司目前具备的各项现实基础、经营能力以及年度经营计划，本着 坚持战略引领，注重价值导向，稳健发展的原则编制而成。 公司根据上年实际情况，认真研判 2025 年度经济形势及市场行情，结合国 内外经济环境及行业运行特点认真分析研究了 2025 年公司发展面临的机遇与挑 战，明确预算落实的思路、措施及策略，对本年度销售计划、采购计划、生产计 划进行了安排、部署及汇总。 二、预算编制的基本假设 1、公司遵循的法律、行政法规、政策及经济环境不发生重大变化: 2、公司所处行业形势、市场需求无重大变化; 3、现行主要 ...

证券代码：603439 证券简称：贵州三力 公告编号：2025-020 为满足公司及子公司经营发展需要，提高资金运营能力，现根据实际生产经 营发展需要和总体发展规划，公司及合并报表范围内子公司拟向银行申请不超过 人民币 15 亿元的综合授信额度，期限为自 2024 年年度股东大会审议通过之日起 至 2025 年年度股东大会召开之日。上述授信额度不等于公司实际融资金额，实 际授信额度最终以银行最后审批的授信额度为准，具体融资金额将视公司运营资 金的实际需求来确定。在授信期限内，授信额度可循环使用。 为提高工作效率，及时办理融资业务，董事会提请股东大会授权公司董事长 及其授权代表根据实际经营情况的需要，在上述授信额度内代表公司办理相关业 务，并签署有关法律文件。根据《上海证券交易所股票上市规则（2024 年 4 月 修订）》和《公司章程》等相关规定，本次申请综合授信事项需提交公司 2024 年年度股东大会审议通过。 特此公告。 贵州三力制药股份有限公司董事会 2025年4月23日 1 贵州三力制药股份有限公司 关于 2025 年度公司及控股子公司 向银行申请综合授信额度的公告 本公司董事会及全体董事保证本公告内容 ...

贵州三力制药股份有限公司 关于2024年度日常关联交易情况及 2025年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要内容提示： 本事项无需提交股东大会审议 日常关联交易对上市公司的影响：贵州三力制药股份有限公司（以下简 称"贵州三力"或"公司"）2024年度日常关联交易所涉及业务全部为正常的经 营性往来，关联交易价格严格遵守了公开、公平、公正及市场化定价的原则，公 司未对关联方形成较大依赖。 证券代码：603439 证券简称：贵州三力 公告编号：2024-017 （单位：万元） | 关联交易 类别 | 关联人 | 2025年度 预计金额 | 占同类业 务比例 （%） | 本年年初至披露日 与关联人累计已发 生的交易金额 | 2024年度实际 发生金额 | 占同类业 务比例 （％） | 本次预计金 额与上年实 际发生金额 差异较大的 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 原因 | | 向关联人 | 贵州永 ...

一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 名称：北京德皓国际会计师事务所（特殊普通合伙） 证券代码：603439 证券简称：贵州三力 公告编号：2025-019 贵州三力制药股份有限公司 关于续聘会计师事务所公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：北京德皓国际会计师事务所（特殊普通合伙） （以下简称"北京德皓国际"）（曾用名：北京大华国际会计师事务所(特殊 普通合伙）） 贵州三力制药股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开 第四届董事会第十二次会议，审议通过了《关于续聘会计师事务所的议案》，同 意续聘北京德皓国际会计师事务所（特殊普通合伙）为公司 2025 年度财务审计 机构和内部控制审计机构，本议案尚需提交公司股东大会审议，现将相关事项公 告如下： 成立日期：2008 年 12 月 8 日 组织形式：特殊普通合伙 注册地址：北京市西城区阜成门外大街 31 号 5 层 519A 首席合伙人：杨雄 截止 2024 年 12 ...

贵州三力制药股份有限公司 2024年度会计师事务所履职情况评估报告 贵州三力制药股份有限公司（以下简称"公司"）聘请北京德皓国际会计师 事务所（特殊普通合伙）（以下简称"北京德皓"）作为公司 2024 年度财务及内 部控制审计机构。根据财政部、国资委及证监会颁布的《国有企业、上市公司 选聘会计师事务所管理办法》，公司对北京德皓 2024 年审计过程中的履职情 况进行评估。经评估，公司认为北京德皓资质等方面合规有效，履职保持独立 性，勤勉尽责，公允表达意见。具体情况如下： 一、资质条件情况 （一）基本信息 截止 2024 年 12 月 31 日，北京德皓近三年因执业行为受到刑事处罚 0 次、 行政处罚 0 次、行政监管措施 1 次、自律监管措施 0 次和纪律处分 0 次。期间 有 30 名从业人员近三年因执业行为受到行政监管措施 22 次（其中 21 次不在本 所执业期间）、自律监管措施 6 次（均不在本所执业期间）。 名称：北京德皓国际会计师事务所（特殊普通合伙） 成立日期：2008 年 12 月 8 日 组织形式：特殊普通合伙 注册地址：北京市西城区阜成门外大街 31 号 5 层 519A 首席合伙人：杨雄 ...

贵州三力制药股份有限公司 2024 年度监事会工作报告 2024 年，贵州三力制药股份有限公司（以下简称"公司"）监事会严格按 照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上海证券交易所股票上市规则》（以 下简称"《股票上市规则》"）、《贵州三力制药股份有限公司章程》（以下简 称"《公司章程》"）、《贵州三力制药股份有限公司监事会议事规则》等有关 法律法规、规范性文件以及公司制度的规定，本着对全体股东负责的态度，认真 履行监督职责，勤勉尽责地开展各项工作，积极有效地发挥了监事会的作用，坚 决贯彻执行股东大会的各项决议，维护公司和股东的合法权益，推动公司持续稳 定发展。 一、 监事会工作情况 2024 年公司监事依法履行职责，主要工作情况如下： （一） 监事会积极关注本公司经营计划及决策，对公司经营决策的程序行 使了监督职责。 （二） 监事会十分关注和重视全资子公司的重大经营活动。 （三） 监事会认真监督董事会对股东大会决议的落实情况，积极维护公 司所有股东的合法权益。 二、 监事会会议召开情况 2024 年度，公司监事会共召开了 10 次会议， ...

贵州三力制药股份有限公司董事会 2025 年 4 月 21 日 经核查在任独立董事归东先生、冯卫生先生、陈世贵先生及离任 独立董事王强先生的任职经历以及签署的相关自查文件，董事会认为： 归东先生、王强先生、陈世贵先生、冯卫生先生均严格遵守了《中 华人民共和国公司法》、《上市公司治理准则》和《上市公司独立董 事管理办法》等法律法规对独立董事的任职等相关要求，在 2024 年 度任职期间未在公司担任除独立董事以外的任何职务，也未在公司主 要股东单位担任任何职务，与公司以及主要股东之间不存在利害关系 或其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独 立性的情况，符合《上市公司独立董事管理办法》、《上海证券交易 所自律监管指引第 1 号——规范运作》中对独立董事独立性的相关要 求。 贵州三力制药股份有限公司董事会 关于公司独立董事 2024 年度独立性情况的专项意见 根据中国证券监督管理委员会《上市公司独立董事管理办法》、 《上海证券交易所上市公司自律监管指引第 1 号——规范运作（2023 年 12 月修订）》等有关规定，并结合独立董事出具的《独立董事关 于独立性情况的自查报告》，贵州三力制药股份有限公 ...

本次会计政策变更系贵州三力制药股份有限公司（以下简称"公司"） 根据中华人民共和国财政部（以下简称"财政部"）的相关规定对公司会计政策 进行的相应变更，无需提交公司董事会、监事会和股东大会审议。 本次会计政策变更不会对公司的财务状况、经营成果和现金流量产生重 大影响。 一、本次会计政策变更概述 证券代码：603439 证券简称：贵州三力 公告编号：2025-025 贵州三力制药股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （一）会计政策变更的原因 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 （四）变更后采用的会计政策 本次会计政策变更后，公司将执行财政部发布的《解释第 18 号》的相关规 定执行，其他未变更部分仍按照财政部前期颁布的《企业会计准则—基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定执行。 （五）变更审议的程序 本次公司会计政策变更为公司根据国家统一会计制度的要求变更，本次变更 ...